Age, gender, and etiology significantly influence prognosis together with the recently validated simplified PAH risk table but don’t significantly influence the response to PAH-specific treatment.
A clinician shares his experience with palliative care in cardiology and makes the case for offering palliative care services earlier in pulmonary arterial hypertension.
Investigators sought to differentiate cardiac exercise responses in patients with pulmonary arterial hypertension stratified according to established measurements of disease severity.
The REVEAL 2.0 three category score was better at discriminating risks in patients with pulmonary arterial hypertension than similar tools such as COMPERA and FPHR.
In patients with pulmonary arterial hypertension, high baseline right atrial pressure, left heart disease, and pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis are valuable predictors of pulmonary edema.
Individuals with pulmonary hypertension experienced lower primary graft dysfunction following heart-lung transplantation compared with double-lung transplantation.
There may be an additive benefit to adding neprilysin inhibitors to PDE5 therapy in patients with pulmonary arterial hypertension.
Researchers sought to determine the safety of left main coronary artery stenting in patients with pulmonary arterial hypertension and extrinsic left main coronary artery compression.
In a review of repurposing medications for pulmonary arterial hypertension treatment, dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support their use.
Investigators sought to determine the efficacy of PDE5 inhibitors to treat pulmonary hypertension in adults and children.
